Exact Sciences (EXAS) shares tumbled 5.35% in pre-market trading on Thursday amid multiple price target cuts from Wall Street analysts.
Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. BTIG also cut its price target on the molecular diagnostics company to $65 from $75, but kept a Buy rating following Exact Sciences' Q4 results and guidance.
Additionally, Jefferies trimmed its price target on EXAS to $80 from $85 as part of its broader research roundup on U.S. companies.